New stock news | Yino Micro Medical Hong Kong IPO prospectus failed
Immvira Bioscience Inc. (referred to as "Immvira") submitted its Hong Kong stock prospectus on June 25th, which expired after 6 months on December 25th. Citigroup and CICC were its joint sponsors at the time of submission.
Immvira Bioscience Inc. (referred to as Immvira Bioscience) submitted its Hong Kong IPO prospectus on June 25, which expired after 6 months on December 25, with Citigroup and CICC as its joint sponsors.
According to the previous prospectus, Immvira Bioscience is a biotechnology company focusing on clinical demand-driven research. It is committed to discovering, developing, producing, and commercializing new oncolytic immunotherapy and engineered exosome therapy through proprietary bioengineering technology. The company designs a risk-sharing product portfolio, including oncolytic immunotherapy candidate drugs with the best potential for treating solid tumors and innovative engineered exosome therapy products with clinical application prospects or direct commercialization potential.
Related Articles
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?
"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).
The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?
"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).
The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
